301207 华兰疫苗
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.2643.34814.62612.51424.863
总资产报酬率 ROA (%)1.8002.64911.4128.96015.199
投入资产回报率 ROIC (%)2.1953.18113.86811.34621.417

边际利润分析
销售毛利率 (%)76.99481.15388.08988.08987.935
营业利润率 (%)17.29019.05141.90432.46238.637
息税前利润/营业总收入 (%)16.95218.39741.56431.98939.018
净利润/营业总收入 (%)16.41618.22235.67728.46333.936

收益指标分析
经营活动净收益/利润总额(%)35.19777.61999.640117.066113.125
价值变动净收益/利润总额(%)51.30746.78410.94212.2905.385
营业外收支净额/利润总额(%)-1.252-0.145-0.315-0.535-0.174

偿债能力分析
流动比率 (X)3.2643.3993.1012.7281.513
速动比率 (X)3.0803.2562.9982.6191.448
资产负债率 (%)20.95620.07321.66622.31637.921
带息债务/全部投入资本 (%)0.0194.4434.1244.85314.595
股东权益/带息债务 (%)530,761.0762,134.3452,307.4211,945.534576.286
股东权益/负债合计 (%)377.184398.192361.563348.118163.703
利息保障倍数 (X)-137.350-29.372-199.512-106.64087.031

营运能力分析
应收账款周转天数 (天)466.555547.106282.792318.997292.040
存货周转天数 (天)348.195323.749213.562227.277124.487